Based in Toronto, Canada, Apotex also operates in the United States, Mexico and India. The company employs close to 8,000 people worldwide in manufacturing, R&D and commercial operations. Its Apobiologix division focuses on biosimilars development.
Here are some of Apotex’s most recent endeavors with the biggest impact:
- Strengthening the supply chain. “Maintaining continuity of supply is our highest priority,” says Lisa Montini, Manager, Corporate Affairs. “And we are constantly looking for improvement opportunities to continue to meet the needs of patients.” The company’s global manufacturing sites can respond quickly to changes in market demands and are capable of a steady supply of active pharmaceutical ingredients (API). Apotex has also increased safety stock for key finished products.
- Corporate Social Responsibility. In 2019, the Apotex Foundation gave $1.25 million to Health Partners International of Canada (HPIC) in support of healthcare projects for some of the world’s most vulnerable communities, including a health clinic in Kenya. In the same year, Apotex also donated more than $1.5 million worth of medicines. The company’s employees regularly volunteer at HPIC to pack donated medicines into Humanitarian Medical Kits for delivery around the world.
- Supporting the battle against COVID. Throughout the COVID pandemic, Apotex has made every effort to help in the battle against the virus. One of its manufacturing sites re-tooled part of its facility to begin production of much-needed hand sanitizer which, along with thousands of N-95 masks, was donated to local health care facilities. Donations of much-needed medication were made to the Canadian and U.S. governments to be used in both COVID-19 clinical trials and patient care. Apotex also partners with AAM associate members Dispensary of Hope and Direct Relief.
Omanna, a woman living in Kerala, India, with a thank-you message for donated medicines. Kerala was devastated by floods in 2018 and 2019.
By Jewel Smith, AAM's Director, Operations
Issues